Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: Report of a case

International Surgery

Volumn 97, Issue 1, 2012, Pages 6-13

  Ochiai, Takanori ^a,b   Masuda, Taiki ^b   Yagi, Masayuki ^b   Kasai, Reo ^b   Furuyama, Takaki ^a,b   Tsukamoto, Kanako ^b   Ito, Hiromitsu ^a,b   Igari, Kimihiro ^b   Aihara, Arihiro ^a,b   Kumagai, Yoichi ^b   Iida, Michio ^b   Odajima, Hajime ^b   Tanaka, Shinji ^a   Arii, Shigeki ^a   Yamazaki, Shigeru ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b OHTA NISHINOUCHI HOSPITAL   (Japan)

Author keywords

Colorectal cancer; FOLFOX; Liver metastases; Liver resection; Lung metastases

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; ASCENDING COLON; CASE REPORT; COLON RESECTION; COLON TUMOR; HUMAN; LIVER RESECTION; LIVER TUMOR; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLON, ASCENDING; COLONIC NEOPLASMS; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS;

EID: 84871195695     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: 10.9738/CC88.1     Document Type: Article

References (33)

1. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005;23(28):7125-7134
2. Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, PintoMet al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 2008;143(4):352-358
3. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343(8910):1405-1410
4. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77(11):1241-1246
5. Sugarbaker PH. Surgical decision making for large bowel cancer metastatic to the liver. Radiology 1990(3 Pt 1);174:621-626
6. Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1988;103(3):278-288
7. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23-30
8. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J ClinOncol 2004;22(7):1209-1214
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342
10. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-1417
11. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-4705
12. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101(7):1033-1038
13. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25(29):4575-4580
14. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19(1):59-71
15. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997;84(7):977-980
16. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230(3):309-318
17. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003;238(6):871-883
18. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005;12(8):637-645
19. Lee WS, Yun HR, Yun SH, Chun HK, Lee WY, Kim SJ et al. Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma. J Gastroenterol Hepatol 2008;23(8 Pt 2):e367-e372
20. Arru M, Aldrighetti L, Castoldi R, Di Palo S, Orsenigo E, Stella M et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg 2008;32(1):93-103
21. Taniai N, Akimaru K, Yoshida H, Tajiri T. Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer. Hepatogastroenterology 2007;54(78):1805-1809
22. Lau WY, Lai EC. Hepatic resection for colorectal liver metastases. Singapore Med J 2007;48(7):635-639
23. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10(6):663-669
24. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2011;34(3):797-807
25. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24(13):2065-2072
26. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007;11(7):860-868
27. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJet al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26(33):5344-5351
28. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatinbased chemotherapy for colorectal liver metastases. Cancer 2007;110(12):2761-2767
29. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94(3): 274-286
30. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7(8):1034-1044
31. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15(3):460-466
32. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008;26(21): 3523-3529
33. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010;17(11):2870-2876